Phase 3 Clinical Trials With Primary Completion Dates in August 2021
This is a list of Phase 3 trials with primary completion dates in August 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| APLIF | Appili Therapeutics Inc. | 2021-08-01 | Phase 3 | NCT04600895 | The Prevent Severe COVID-19 (PRESECO) Study |
| AUPH | Aurinia Pharmaceuticals Inc. | 2021-08-01 | Phase 3 | NCT03597464 | Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin |
| CDTX | Cidara Therapeutics, Inc. | 2021-08-01 | Phase 3 | NCT03667690 | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis |
| CFRX | ContraFect Corporation | 2021-08-01 | Phase 3 | NCT04160468 | Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase |
| CTSO | Cytosorbents Corporation | 2021-08-01 | Phase 3 | NCT04643639 | Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis |
| CVAC | CureVac N.V. | 2021-08-01 | Phase 3 | NCT04838847 | A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 |
| ERYP | ERYTECH Pharma S.A. | 2021-08-01 | Phase 3 | NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC |
| IPSEY | Ipsen S.A. | 2021-08-01 | Phase 3 | NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer |
| KRYS | Krystal Biotech, Inc. | 2021-08-01 | Phase 3 | NCT04491604 | The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). |
| NMTR | 9 Meters Biopharma, Inc. | 2021-08-01 | Phase 3 | NCT03569007 | Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms |
| RIGL | Rigel Pharmaceuticals, Inc. | 2021-08-01 | Phase 3 | NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects |
| TBPH | Theravance Biopharma, Inc. | 2021-08-01 | Phase 3 | NCT03750552 | Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure |
| UTHR | United Therapeutics Corporation | 2021-08-01 | Phase 3 | NCT01560637 | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension |